Co-morbidity of drug addiction: An analysis of epidemiological data and possible etiological models

被引:8
|
作者
Demetrovics, Zsolt [1 ]
机构
[1] Eotvos Lorand Univ, Addict Res Unit, H-1580 Budapest, Hungary
关键词
Substance use disorder; co-morbidity; models of co-morbidity; self-medication; SUBSTANCE USE DISORDERS; COMORBID PSYCHIATRIC-DISORDERS; III PERSONALITY-DISORDERS; CANNABIS USE; BIPOLAR DISORDER; OPIATE ADDICTS; MENTAL-HEALTH; ANXIETY DISORDERS; OPIOID ADDICTS; YOUNG-PEOPLE;
D O I
10.1080/16066350802601324
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
This review summarizes the literature on psychiatric co-morbidity of substance use. The author overviews general population epidemiological surveys as well as clinical studies, and discusses both DSM axis I and axis II disorders. After presenting epidemiological data the author analyzes the nature of relationship between psychoactive substance use and other mental disorders, and-through examples-four possible models of this relationship are examined. Despite the lack of precisely determined prevalence rates, some definite tendencies could be observed along the consistent results of the studies. Due to methodological problems, however, many questions remain unanswered. Although there are relatively comprehensive studies on psychiatric disorders associated with drug use and drug addiction, the question of causality is relatively unresolved. Theoretically possible relations regarding causality seem to overlap in practice, and in most cases linear type connection is unlikely. It can be concluded that general questions, such as which disorders have a great significance in connection to drug use, can be answered. Additional research is needed, however, to examine the effects of different drug types, race, and gender. Understanding causality also requires further research.
引用
收藏
页码:420 / 431
页数:12
相关论文
共 50 条
  • [22] Co-morbidity among drug abusers: Influences on compliance with treatment
    Ravndal, E
    EUROPEAN PSYCHIATRY, 2000, 15 : 62 - 62
  • [23] DISC1 signaling in cocaine addiction: Towards molecular mechanisms of co-morbidity
    Gancarz, Amy
    Jouroukhin, Yan
    Saito, Atsushi
    Shevelkin, Alexey
    Mueller, Lauren E.
    Kamiya, Atsushi
    Dietz, David M.
    Pletnikov, Mikhail V.
    NEUROSCIENCE RESEARCH, 2016, 105 : 70 - 74
  • [24] COGNITION AND IMPULSIVITY RELATED BRAIN VOLUME CHANGES IN SCHIZOPHRENIA-ADDICTION CO-MORBIDITY
    Schiffer, Boris
    Mueller, Bernhard W.
    Gizewski, Elke R.
    SCHIZOPHRENIA RESEARCH, 2010, 117 (2-3) : 425 - 425
  • [25] Psychiatric co-morbidity and medical illness in adults with mild intellectual disabilities: Epidemiological findings
    Deman, P.
    JOURNAL OF INTELLECTUAL DISABILITY RESEARCH, 2008, 52 : 732 - 732
  • [26] Co-morbidity and Age-related Prevalence of Psoriasis: Analysis of Health Insurance Data in Germany
    Augustin, Matthias
    Reich, Kristian
    Glaeske, Gerd
    Schaefer, Ines
    Radtke, Marc
    ACTA DERMATO-VENEREOLOGICA, 2010, 90 (02) : 147 - 151
  • [27] Co-morbidity is the norm, not the exception: chronic respiratory diseases in chronic drug users
    Kim, Theresa W.
    Samet, Jeffrey H.
    PRIMARY CARE RESPIRATORY JOURNAL, 2012, 21 (04): : 364 - 365
  • [28] Drug use and young people: why is co-morbidity research so important?
    Zeitlin, H
    ADDICTION, 2000, 95 (11) : 1619 - 1620
  • [29] Restless legs syndrome among women:: prevalence, co-morbidity and possible relationship to menopause
    Wesstrom, J.
    Nilsson, S.
    Sundstrom-Poromaa, I.
    Ulfberg, J.
    CLIMACTERIC, 2008, 11 (05) : 422 - 428
  • [30] The psychiatric diagnostic screening questionnaire is an effective screening measure for co-morbidity within addiction services.
    Rolfe, Joanne
    Roche, Declan
    Sarma, Kiran
    Bogue, John
    PSYCHOLOGY & HEALTH, 2013, 28 : 300 - 300